Halia Therapeutics Appoints Paul Jones to Lead GENMOR-AI Platform

October 06, 2025
Halia Therapeutics has appointed Paul Jones as Chief Strategy Officer & GM, International Markets to accelerate its GENMOR-AI platform, according to a press release.

Halia Therapeutics has appointed Paul Jones as Chief Strategy Officer & GM, International Markets, announced in a press release. In this newly created role, Jones will focus on accelerating GENMOR-AI, the company's proprietary platform for identifying genetic modifiers of disease using artificial intelligence.

Jones brings over 30 years of experience in life sciences, with expertise in genomics and digital health transformation. His previous roles include CEO of the Omics Centre of Excellence at M42 and Global Head of Population Genomics at Illumina. His appointment aims to strengthen Halia's APOE4 program in Alzheimer's disease and expand partnerships with entities like the Department of Health – Abu Dhabi.

Halia Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies based on genetic resilience, targeting inflammatory pathways in various diseases. The company is leveraging AI and genetic insights to build a pipeline of novel therapeutics.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

10/06
AstraZeneca and Algen Biotechnologies Partner for AI-Driven Gene-Editing Therapies
10/06
Made Scientific and Streamline Bio Validate AI-Driven Robotics for Cell Therapy
10/06
Heidi Secures $65 Million to Expand AI Healthcare Tool
10/06
Microsoft-Led Study Reveals AI-Crafted Toxins Evade DNA Screens
10/06
Embleema Secures $5M DoD Contract for Global Pathogen Detection

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like